© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Nippon Shinyaku Co., Ltd. (NPPNY) stock declined over -3.64%, trading at $5.30 on OTC, down from the previous close of $5.50. The stock opened at $5.30, fluctuating between $5.30 and $5.30 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | 5.30 | 5.30 | 5.30 | 5.30 | 23 |
| Aug 17, 2026 | 5.50 | 5.61 | 5.50 | 5.61 | 270 |
| Aug 14, 2026 | 5.27 | 5.71 | 5.27 | 5.71 | 424 |
| Aug 07, 2026 | 6.12 | 6.12 | 6.12 | 6.12 | 1 |
| Aug 03, 2026 | 5.90 | 5.90 | 5.90 | 5.90 | 27 |
| Jul 27, 2026 | 6.11 | 6.11 | 6.11 | 6.11 | 108 |
| Jul 24, 2026 | 6.29 | 6.29 | 6.00 | 6.00 | 603 |
| Jul 22, 2026 | 6.00 | 6.00 | 6.00 | 6.00 | 10 |
| Jun 29, 2026 | 6.00 | 6.00 | 6.00 | 6.00 | 517 |
| Jun 26, 2026 | 6.00 | 6.00 | 6.00 | 6.00 | 112 |
| Jun 18, 2026 | 6.16 | 6.16 | 6.16 | 6.16 | 645 |
| Jun 12, 2026 | 6.33 | 6.33 | 6.12 | 6.12 | 219 |
| May 29, 2026 | 6.10 | 6.10 | 6.10 | 6.10 | 1.33K |
| May 20, 2026 | 6.66 | 6.66 | 6.66 | 6.66 | 100 |
| May 18, 2026 | 6.50 | 6.50 | 6.50 | 6.50 | 731 |
| Mar 30, 2026 | 7.40 | 7.40 | 7.40 | 7.40 | 357 |
| Mar 24, 2026 | 8.62 | 8.62 | 8.62 | 8.62 | 459 |
| Mar 23, 2026 | 8.07 | 8.07 | 8.07 | 8.07 | 3.81K |
| Mar 17, 2026 | 8.71 | 8.71 | 8.71 | 8.71 | 1 |
| Mar 10, 2026 | 8.43 | 8.45 | 8.43 | 8.45 | 20.2K |
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
| Employees | 2309 |
| Beta | -0.32 |
| Sales or Revenue | $170.77B |
| 5Y Sales Change% | 0.401% |
| Fiscal Year Ends | March |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |